How Precision Medicine Is Reshaping Cancer Survival Curves with CAR-T, Bispecific Antibodies, and Gene Therapy

By:DengYue International Business Division

Against the backdrop of rapidly evolving oncology treatments, understanding the relationships and boundaries between different therapeutic modalities has become increasingly important. Based on Dengyuemed’s continuous tracking of global clinical data and real-world treatment pathways, CAR-T therapy, bispecific antibodies, and gene therapy are no longer isolated technological modules—they are gradually forming a combinational treatment ecosystem.

Over the past decade, the core paradigm of cancer treatment has undergone a fundamental shift. The focus has moved from tumor-type-based standardized approaches to individualized decision-making driven by molecular characteristics and immune status. Innovative strategies represented by CAR-T therapy, bispecific antibodies, and gene editing technologies are redefining the boundaries of “survival benefit.”

Clinically, this transformation is already reflected in survival curves: some patients are transitioning from short-term remission to long-term disease control, and even sustained remission. The traditionally steep decline following a survival plateau is, in certain subgroups, becoming flatter—or even shifting upward.

1. From Molecular Stratification to Treatment Pathway Design

The foundation of precision medicine lies in more refined patient stratification.

Through next-generation sequencing (NGS), immune biomarker evaluation, and dynamic monitoring tools such as liquid biopsy, clinicians can construct increasingly comprehensive “molecular profiles,” including driver mutations, antigen expression, tumor mutational burden (TMB), and characteristics of the tumor microenvironment.

On this basis, treatment evolves from a single-option decision into a pathway-oriented strategy:

● Multiple myeloma patients with high BCMA expression may prioritize dual-target CAR-T or sequential strategies

● Patients with CLDN18.2-positive gastric cancer may transition between bispecific antibodies and cell therapies in staged approaches

● Solid tumors driven by specific mutations may benefit from gene editing or engineered cell therapies for functional enhancement

This shift—from “drug selection” to “pathway design”—fundamentally reduces the probability of ineffective treatments and enables synergy between different technologies.

2. CAR-T: From Single Breakthrough to System Optimization

CAR-T therapy is entering a new phase centered on engineering optimization.

Dual-target designs (e.g., BCMA/CD19) are increasingly used to mitigate antigen escape, while low-dose strategies and manufacturing improvements are enhancing safety and accessibility. Emerging evidence suggests that lower doses can still achieve effective tumor control while significantly reducing the incidence of cytokine release syndrome (CRS).

In addition, early research into in vivo CAR-T generation aims to simplify the treatment process and reduce waiting times—an especially critical factor for patients with rapidly progressing disease.

With precise patient matching, CAR-T is evolving from delivering “deep remission” to enabling “durable disease control,” contributing to structural changes in survival curves.

3. Bispecific Antibodies: The “Middle Layer” Connecting Treatment Stages

Compared to CAR-T, bispecific antibodies offer higher standardization and accessibility, positioning them as a flexible component within treatment pathways.

T-cell engager bispecifics can rapidly activate immune responses, while combination designs such as PD-1/VEGF bispecifics demonstrate advantages in modulating the tumor microenvironment. In certain solid tumors, these therapies not only exert direct antitumor effects but also help prepare the microenvironment for subsequent cell therapies.

In clinical practice, bispecific antibodies are increasingly used for:

● Bridging therapy before CAR-T

● Maintenance or consolidation after CAR-T

● Alternative treatment for patients ineligible for cell therapy

This bridging role makes bispecific antibodies a key element in precision oncology systems.

4. Gene Therapy: From Repair to Reconstruction

Gene editing technologies, such as CRISPR/Cas systems, provide a more fundamental level of intervention in precision medicine.

They can directly target disease-causing genes and are also widely used to engineer immune cells. For instance, gene editing can enhance CAR-T persistence, reduce immune suppression, or introduce safety switches.

From a development perspective, gene therapy is expanding from single-disease applications to multi-scenario use cases, increasingly integrating with cell therapies. This “engineering layering” may represent a critical pathway to raising the upper limit of therapeutic efficacy.

5. Structural Changes in Survival Curves

The combinational application of multiple technologies is reshaping long-term outcomes in certain cancers.

Real-world data and multicenter studies have shown:

● Significant extension of median overall survival in some advanced-stage patients

● Increasing rates of MRD negativity in hematologic malignancies

● Gradual improvement in disease control rates in solid tumors

● Expanded accessibility for elderly patients through lower-toxicity regimens

These improvements are not driven by a single technology but by more precise matching and integration of therapies.

6. From Technological Progress to Clinical Decision-Making

As treatment options expand, new challenges emerge: how to select the most appropriate pathway among multiple strategies.

In this context, experience in interpreting clinical data and aligning treatment pathways is becoming increasingly valuable. Platforms such as Dengyue Pharma, which participate in cross-regional medical information integration, focus more on continuous clinical data tracking, indication matching, and pathway evaluation rather than promoting any single therapy.

This reflects a key reality of the precision medicine era: the value of information lies not only in access but in interpretation and application.

Conclusion

Current trends suggest that CAR-T, bispecific antibodies, and gene therapy are collectively driving oncology into a new phase. Their value extends beyond tumor control, gradually expanding into broader immune system modulation.

Dual-target strategies, represented by BCMA/CD19, may serve as a key pivot in this transition. Although data are still accumulating, the overall direction is becoming increasingly clear.

In the coming years, as more clinical evidence emerges, the positioning of these technologies across different diseases will be further defined. Throughout this process, the ability to continuously track data and make informed pathway decisions will remain a crucial link between cutting-edge innovation and real-world clinical practice.

For more insights into frontier medical advancements, follow the ongoing updates from HK Dengyuemed.

Disclaimer

This article is based on publicly available clinical studies, conference data, and real-world evidence as of the end of March 2026 (including ClinicalTrials.gov, ASGCT, ASCO, etc.). Specific treatment plans should be determined based on individual patient conditions under the guidance of qualified medical professionals.